Novo Nordisk AS's highly promising Phase II trial data for its new GLP-1 agonist semaglutide and the resultant full-steam ahead progression into Phase III could open up a large new market for the investigational antidiabetic, but it seems most of it will come at the expense of the company's older GLP-1 agonist Saxenda (liraglutide). Moreover, a change in attitudes will be needed for the product to reap its full rewards in this difficult market.
Novo Nordisk Will Eat Itself In Obesity
The Danish diabetes specialist is forging ahead with pivotal trials for its latest GLP-1 offering semaglutide in obesity after highly impressive Phase II efficacy data, but is likely to take the biggest market share from its own product, Saxenda.
More from Business
More from Scrip
• By
The San Diego biotech’s lead product candidate is an antisense oligonucleotide-based therapy slated to enter Phase III development in the third quarter.
• By
The company’s FcRn inhibitor nipocalimab was approved by the US FDA for generalized myasthenia gravis (gMG), where it will join a competitive market.
• By
Merck is investing $ 1bn in a Delaware facility to produce Keytruda and expand biologics manufacturing amid US tariff concerns.